Valuation: Glaukos Corporation

Market Cap 965.4Cr 857.76Cr 800.58Cr 729.7Cr 1.38TCr 93TCr 1.39TCr 9.69TCr 3.75TCr 47TCr 3.62TCr 3.55TCr 1,52300Cr P/E 2026 *
-203x
P/E 2027 * 504x
Enterprise Value 947.92Cr 842.22Cr 786.08Cr 716.48Cr 1.35TCr 91TCr 1.36TCr 9.51TCr 3.69TCr 47TCr 3.56TCr 3.48TCr 1,49500Cr EV / Sales 2026 *
13.7x
EV / Sales 2027 * 11x
Free-Float
96.38%
Yield 2026 *
-
Yield 2027 * -
1 day+0.36%
1 week+6.04%
Current month-0.27%
1 month-7.73%
3 months+10.39%
6 months+45.21%
Current year+45.03%
1 week 152.39
Extreme 152.39
168.73
1 month 151.01
Extreme 151.01
185.35
Current year 93.96
Extreme 93.96
191.62
1 year 73.16
Extreme 73.16
191.62
3 years 59.22
Extreme 59.22
191.62
5 years 33.33
Extreme 33.33
191.62
10 years 23.08
Extreme 23.075
191.62
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2001
Director of Finance/CFO 56 01/04/2022
President 50 01/04/2022
Director TitleAgeSince
Chairman 65 31/12/2021
Director/Board Member 71 01/07/2014
Director/Board Member 57 01/07/2014
Date Insider Type Main position Quantity % Market Cap. Importance
25/09/26 Sell

Executive/Senior Manager

-1,615 0.0028%
16/09/26 Sell

Executive/Senior Manager

-1,457 0.0025%
28/08/26 Sell

Executive/Senior Manager

-13,744 0.0240%
Change 5-day change 1-year change 3-year change Capi.($)
+0.36%+6.04%+87.34%+136.46% 965.4Cr
+0.84%-3.74%-27.56%+1.93% 17TCr
-0.07%-2.55%-11.59%+13.26% 11TCr
+0.90%+1.13%-25.66%+3.47% 11TCr
+1.30%-0.99%-47.61%-11.26% 7.39TCr
-0.24%+0.69%+2.08%+69.19% 5.9TCr
+1.32%+3.86%+8.58%+61.88% 5.13TCr
-0.71%-3.82%-8.68%-31.93% 4.82TCr
+0.12%-0.17%-17.87%+19.66% 4.08TCr
-1.01%-1.45%+27.31%-2.67% 3.22TCr
Average +0.28%-0.17%-1.37%+26.00% 7TCr
Weighted average by Cap. +0.46%-1.19%-15.75%+12.97%

Financials

2026 *2027 *
Net sales 69Cr 61Cr 57Cr 52Cr 99Cr 6.64TCr 99Cr 693.47Cr 268.72Cr 3.4TCr 259.44Cr 253.81Cr 11TCr 85Cr 76Cr 71Cr 64Cr 121.2Cr 8.17TCr 122.33Cr 853.27Cr 330.64Cr 4.18TCr 319.22Cr 312.29Cr 13TCr
Net income -5.19Cr -4.61Cr -4.3Cr -3.92Cr -7.39Cr -498.62Cr -7.46Cr -52Cr -20Cr -254.9Cr -19Cr -19Cr -818.08Cr 1.91Cr 1.7Cr 1.59Cr 1.45Cr 2.73Cr 184Cr 2.75Cr 19Cr 7.44Cr 94Cr 7.19Cr 7.03Cr 301.89Cr
Net Debt -17Cr -16Cr -15Cr -13Cr -25Cr -1.68TCr -25Cr -175.51Cr -68Cr -859.45Cr -66Cr -64Cr -2.76TCr -27Cr -24Cr -23Cr -21Cr -39Cr -2.62TCr -39Cr -273.8Cr -106.1Cr -1.34TCr -102.44Cr -100.21Cr -4.3TCr
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
02/26/02 $163.75 +0.36% 7,42,806
01/26/01 $163.17 -0.62% 8,08,411
30/26/30 $164.19 +3.56% 9,47,091
29/26/29 $158.55 -0.01% 6,38,201
28/26/28 $158.56 +2.67% 14,00,531
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
163.75USD
Average target price
198.69USD
Spread / Average Target
+21.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock